What are analysts expecting for Pfizer's Q1 2025 earnings?
Analysts expect earnings of $0.60 per share and revenue of $13.97 billion.
Yanuki
ARTICLE DETAIL
Pfizer Q1 Earnings Preview: Analysts Sound Caution | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026 | Pfizer Q1 Earnings Preview: Analysts Sound Caution | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026
Finance / Earnings
Pfizer Q1 Earnings Preview: Analysts Sound Caution
Analysts are approaching Pfizer's Q1 2025 earnings report with caution, citing patent expirations and competitive pressures. However, growth in non-COVID-related products offers a glimmer of optimism. The report is due on April 29th.
Key Insights
- Analysts expect Pfizer to report earnings of $0.60 per share, down from $0.82 a year ago.
- Revenue is projected at $13.97 billion, compared to $14.88 billion in Q1 2024.
- Vyndaqel family of drugs is expected to drive strong growth with double-digit sales increases. Why does this matter? Vyndaqel's performance is crucial for offsetting revenue declines from other areas.
- Bank of America Securities lowered the price target on PFE stock from $29.00 to $26.00, maintaining a Hold rating due to uncertainty around long-term growth prospects.
- Goldman Sachs also reiterated its Hold rating with a price target of $25, emphasizing the need for clarity around Pfizer’s M&A strategy and drug pipeline development.
In-Depth Analysis
Pfizer (PFE) faces headwinds from patent expirations on blockbuster drugs like Ibrance and Eliquis, as well as looming drug-pricing reforms. Investors are keen to hear management's strategies for defending its vaccine and oncology franchises and updates on the pipeline to counter the patent cliff.
Despite these challenges, Pfizer's stock may offer value. GuruFocus estimates fair value at $28.82, about 25% above recent closes. The company has a history of exceeding EPS forecasts, doing so in each of the last eight quarters, and beating revenue estimates in five of those periods.
However, analysts at Bank of America Securities and Goldman Sachs maintain Hold ratings on PFE, reflecting concerns about long-term growth and the need for greater clarity on strategic initiatives. Investors should closely monitor Pfizer's Q1 earnings call for insights into these critical areas.
FAQ
What is driving growth for Pfizer?
The Vyndaqel family of drugs, which treat a rare heart condition, is expected to drive strong growth.
What are the main concerns for Pfizer?
Patent expirations, increasing competition, and uncertainty around long-term growth prospects.
Takeaways
- Monitor Pfizer's Q1 earnings call for updates on patent expirations and pipeline development.
- Pay attention to the performance of Vyndaqel as a key growth driver.
- Be aware of the cautious stance from analysts due to long-term growth concerns.
- Consider Pfizer's potential undervaluation based on fair value estimates.
Discussion
Do you think Pfizer can overcome its challenges and deliver strong growth? Let us know!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.